Prof Chris Goldring


Professor Chris Goldring obtained a BSc in Biochemistry at Liverpool John Moores University in 1986; a PhD in Biochemistry at Guy’s Hospital, London, in 1991; and a PGCert in Learning and Teaching, the University of Liverpool in 2011.  He was a Wellcome Trust Travelling Research Scholar to Xi’an University, China, 1988-1989, Erasmus Visiting Scholar at the University of Siena, Italy, 1991. He previously carried out research and lectured at the Ecole Pratique des Hautes Etudes, University of Bourgogne, France and the Department of Nephrology, Bern University Hospital, Switzerland, before moving to the Drug Safety Group at the University of Liverpool, in 1999. He now leads the molecular and cellular toxicology group within the MRC Centre for Drug Safety Science (CDSS), a leading UK centre at the Universities of Liverpool and Manchester, with a critical mass of scientists studying mechanisms of adverse reactions to drugs. 

Chris Goldring has nearly twenty years' experience of molecular bioanalysis, working with cell culture and in-vivo models, and has largely focused on understanding transcriptional control in the liver. He has more than 60 journal and conference papers published to date. He has current MRC, Wellcome Trust and BBSRC support. He is a supported member of the Stem Cells for Safer Medicines Consortium, and has had project grant support from the Wellcome Trust and BBSRC (New Investigator award). He has been a panel member of Biotech grant committees for Enterprise Ireland, and he leads a teaching programme on Safety Pharmacology in the Innovative Medicines Initiative. 



For a full list of publications please visit: